These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

638 related items for PubMed ID: 27393514

  • 1. Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM, Lai CH, Rau KM, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Chen YC, Chung YH, Wang YH, Su MC, Huang KT, Liu SF, Chen HC, Chang YC, Chang YP, Wang CC, Lin MC.
    Lung Cancer; 2016 Aug; 98():99-105. PubMed ID: 27393514
    [Abstract] [Full Text] [Related]

  • 2. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH, Lin D, Xu L, Wang Q, Hu HH, Xu HP, He ZY.
    Oncotarget; 2017 Jan 10; 8(2):3412-3421. PubMed ID: 27926500
    [Abstract] [Full Text] [Related]

  • 3. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD, Park KH, Park CK, Lee SH, Kim SJ, Yoon HK, Lee YS, Lee EJ, Lee KY, Kim TJ.
    Lung Cancer; 2015 Mar 10; 87(3):311-7. PubMed ID: 25617986
    [Abstract] [Full Text] [Related]

  • 4. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Zhang X, Fan J, Li Y, Lin S, Shu P, Ni J, Qin S, Zhang Z.
    Tumour Biol; 2016 Jan 10; 37(1):1061-9. PubMed ID: 26269114
    [Abstract] [Full Text] [Related]

  • 5. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM, Lai CH, Rau KM, Huang CH, Chang HC, Chao TY, Tseng CC, Fang WF, Chung YH, Wang YH, Su MC, Huang KT, Liu SF, Chen HC, Chang YC, Chang YP, Wang CC, Lin MC.
    BMC Cancer; 2016 Nov 08; 16(1):868. PubMed ID: 27821111
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL, Han G, Peng M, Weng YM, Yuan JP, Yang GF, Yu JM, Song QB.
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec 08; 37(6):864-872. PubMed ID: 29270745
    [Abstract] [Full Text] [Related]

  • 7. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS, Cho BC, Soo RA.
    Lung Cancer; 2016 Mar 08; 93():59-68. PubMed ID: 26898616
    [Abstract] [Full Text] [Related]

  • 8. The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.
    Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, Wang CC, Chung YH, Wang YH, Su MC, Huang KT, Chen HC, Lin MC.
    Lung Cancer; 2016 Mar 08; 93():47-54. PubMed ID: 26898614
    [Abstract] [Full Text] [Related]

  • 9. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Yoshida T, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y, Goto K.
    Lung Cancer; 2015 Dec 08; 90(3):477-83. PubMed ID: 26604031
    [Abstract] [Full Text] [Related]

  • 10. Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
    Hong SH, Kim YS, Lee JE, Kim IH, Kim SJ, Han D, Yoo IeR, Chung YG, Kim YH, Lee KY, Kang JH.
    Cancer Res Treat; 2016 Jul 08; 48(3):1110-9. PubMed ID: 26790969
    [Abstract] [Full Text] [Related]

  • 11. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
    Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL, Zhou Q.
    Thorac Cancer; 2016 Nov 08; 7(6):648-654. PubMed ID: 27755835
    [Abstract] [Full Text] [Related]

  • 12. Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC.
    Wang BX, Ou W, Mao XY, Liu Z, Wu HQ, Wang SY.
    Clin Neurol Neurosurg; 2017 Sep 08; 160():96-100. PubMed ID: 28704781
    [Abstract] [Full Text] [Related]

  • 13. Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.
    Okuma Y, Kashima J, Watanabe K, Homma S.
    J Cancer Res Clin Oncol; 2018 Aug 08; 144(8):1601-1611. PubMed ID: 29858682
    [Abstract] [Full Text] [Related]

  • 14. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
    Kanda S, Horinouchi H, Fujiwara Y, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Kubota K, Tamura T, Ohe Y.
    Lung Cancer; 2015 Sep 08; 89(3):287-93. PubMed ID: 26169499
    [Abstract] [Full Text] [Related]

  • 15. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Kogure Y, Saka H, Oki M, Saito TI, Ahmed SN, Kitagawa C, Imaizumi K.
    PLoS One; 2015 Sep 08; 10(8):e0135393. PubMed ID: 26262682
    [Abstract] [Full Text] [Related]

  • 16. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun 08; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 17. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K, Hata A, Kaji R, Fujita S, Otoshi T, Fujimoto D, Kawamura T, Tamai K, Takeshita J, Matsumoto T, Monden K, Nagata K, Otsuka K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K, Katakami N.
    J Thorac Oncol; 2013 Jul 08; 8(7):892-8. PubMed ID: 23591159
    [Abstract] [Full Text] [Related]

  • 18. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.
    J Thorac Oncol; 2011 Apr 08; 6(4):707-15. PubMed ID: 21258250
    [Abstract] [Full Text] [Related]

  • 19. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Heideman DA, Berk Y, Buijs EJ, Speel EJ, Krouwels FH, Smit HJ, Groen HJ, Dingemans AM, Smit EF.
    Lung Cancer; 2015 Sep 08; 89(3):255-61. PubMed ID: 26117231
    [Abstract] [Full Text] [Related]

  • 20. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Kashima J, Okuma Y, Miwa M, Hosomi Y.
    Med Oncol; 2016 Nov 08; 33(11):129. PubMed ID: 27757781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.